Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099-1142.
Tepper DE. Calcitonin gene-related peptide targeted therapy for migraine. Headache. 2016;56:447-448.
MaassenVanDenBrink A, Terwindt GM, van den Maagdenberg AMJM. Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment. Genome Med. 2018;10:10.
ClinicalTrials.gov. Safety and efficacy study in adult subjects with acute migraines. https://clinicaltrials.gov/ct2/show/NCT03235479. Accessed August 7, 2018.
ClinicalTrials.gov. Efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine. https://clinicaltrials.gov/ct2/show/NCT02867709. Accessed August 7, 2018.
ClinicalTrials.gov. Efficacy, safety, and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention. https://clinicaltrials.gov/ct2/show/NCT02848326. Accessed August 7, 2018.
AIMOVIG® [package insert]. Thousand Oaks, California: Amgen, Inc.; 2018.
ClinicalTrials.gov. Evaluation of ALD403 (eptinezumab) in the prevention of chronic migraine (PROMISE 2). https://clinicaltrials.gov/ct2/show/NCT02974153. Accessed August 6, 2018.
Teva Pharmaceutical Industries Ltd. Teva provides update on clinical trial of fremanezumab for use in chronic cluster headache [press release]. June 15, 2018. https://www.drugs.com/clinical_trials/teva-provides-update-clinical-trial-fremanezumab-chronic-cluster-headache-17842.html. Accessed August 6, 2018.
Eli Lilly and Company. FDA accepts biologics license application (BLA) to review galcanezumab for the prevention of migraine in adults [press release]. December 11, 2017. http://lilly.mediaroom.com/index.php?s=9042&item=137736. Accessed August 6, 2018.
Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral cgrp receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, study 302. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Presentation IOR02LB.
Dodick DJ, Lipton RB, Ailani J, et al. Ubrogepant for the acute treatment of migraine: efficacy, safety, tolerability, and functional impact outcomes from a single attack phase III study, ACHIEVE I. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Presentation IOR01LB.
ClinicalTrials.gov. Efficacy, safety, and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention. https://clinicaltrials.gov/ct2/show/NCT02848326. Accessed August 6, 2018.
Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18:96.
Reuter U. A review of monoclonal antibody therapies and other preventative treatments in migraine. Headache. 2018;58 Suppl 1:48-59.
Lipton RB, Diamond ML, Tepper SJ. Expert perspectives -- migraine prevention for highly impacted patients. US Neurology. 2018;14:3–10.
Bolay H, Durham P. Biological sciences for headache: pharmacology. Handb Clin Neurol. 2010;97:47-71.
Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40:S1-S80.
Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593-601.
Saper J, Lipton R, Kudrow D, et al. Primary results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) trial: a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines (S20.001). Neurology. 2018;90:S20.001.
Winner PK, et al. Eptinezumab reduced migraine activity and achieved high migraine responder rates over weeks 1‒12: results from the phase 3 PROMISE-2 trial in chronic migraine. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Presentation IOR-03.
Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132.
Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia.2018;38:1026-1037.
Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018. doi: 10.1001/jamaneurol.2018.1212. [Epub ahead of print]
Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442-1454.
Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999-2008.
Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113-2122.
Winner PK, Bigal ME, Aycardi E, et al. Achievement of response with fremanezumab in the treatment of chronic migraine. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Presentation IOR-11.
Saper J, Diamond M, Huffman C, et al. Migraine activity reductions with eptinezumab were associated with improvements in short-form health survey scores most affected by migraine: results from phase 3 PROMISE-2 trial in chronic migraine. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Poster PF06.
Ashina M, Tepper SJ, Brandes Jan, et al. Long-term efficacy of erenumab in patients with cm and prior prophylactic treatment failure. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Poster PF106LB.
Aurora S, Detke H, Millen B, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: post-hoc analyses of two phase 3 studies. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Presentation IOR-05.
Silberstein SD, Ashina S, Katsarava Z, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine. Presented at: 60th Annual Scientific Meeting American Headache Society; June 28-July 1, 2018; San Francisco, CA. Presentation IOR-07.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

David W. Dodick, MD

Professor of Neurology
Mayo Clinic College of Medicine
Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Disclosures

Disclosure: David Dodick, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acorda Therapeutics; Alcobra Ltd.; Alder Biopharmaceuticals Inc.; Allergan, Inc.; Amgen Inc.; Arteaus Therapeutics; Autonomic Technologies, Inc.; Biohaven Pharmaceuticals; BioVentrix; Boston Scientific; Bristol-Myers Squibb Company; Charleston Laboratories, Inc.; CoLucid Pharmaceuticals, Inc.; Dr. Reddy's Laboratories; ElectroCore Medical, LLC; Eli Lilly and Company; eNeura Therapeutics; Ethicon US, LLC; GBS/Nocira; IMPAX Laboratories, Inc.; INSYS Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Labrys Biologics, Inc.; Lundbeck, Inc.; Magellan Health, Inc; MAP Pharmaceuticals, Inc.; Medtronic, Inc; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; NuPathe, Inc.; Pfizer Inc.; Promius Pharma, LLC; St. Jude Medical; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Theranica Bio-Electronics Ltd.; Tonix Pharmaceuticals Holding Corp.; W. L. Gore & Associates, Inc.; Xenon Pharmaceuticals Inc.; Zogenix, Inc.; Zosano Pharma Corporation
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Amgen Inc.; CoLucid Pharmaceuticals, Inc.; Eli Lilly and Company; Medicom; Novartis Pharmaceuticals Corporation
Owns stock, stock options, or bonds from: EPIEN Medical, Inc; Healint; Nocira LLC; Theranica Bio-Electronics Ltd.

Dr Dodick does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Dodick does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

Richard Lipton, MD

Edwin S. Lowe Chair in Neurology
Albert Einstein College of Medicine
Director
Montefiore Headache Center
Bronx, New York

Disclosures

Disclosure: Richard Lipton, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alder Biopharmaceuticals, Inc.; Allergan, Inc.; Amgen Inc.; Autonomic Technologies, Inc.; Avanir Pharmaceuticals; Biohaven Pharmaceuticals; BioVision Inc.; Boston Scientific; Dr. Reddy's Laboratories; ElectroCore Medical, LLC; Eli Lilly and Company; eNeura Therapeutics; GlaxoSmithKline; Merck & Co., Inc.; Pernix Therapeutics; Pfizer Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Trigemina, Inc.; Vector Therapeutics Corp.; Vedanta Biosciences, Inc.
Owns stock, stock options, or bonds from: Biohaven Pharmaceuticals; eNeura Therapeutics

Dr Lipton does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lipton does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Pakinam Aboulsaoud, PharmD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Catherine Friederich Murray BS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Catherine Friederich Murray, BS, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Getting to Grips With the Science of CGRP and Migraine

Authors: David W. Dodick, MD; Richard Lipton, MD
CME / ABIM MOC Released: 8/24/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 8/24/2019

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, and obstetricians/gynecologists.

The goal of this activity is to provide understanding of the pathophysiology of migraine and the latest advancements in migraine therapies targeting calcitonin gene-related peptide (CGRP).

Upon completion of this activity, participants will have increased knowledge regarding the:

Pathophysiology of migraine
Mechanism of action of currently available and novel therapies in development for migraine

Disclosures

Moderator

David W. Dodick, MD

Professor of Neurology
Mayo Clinic College of Medicine
Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Disclosures

Disclosure: David Dodick, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acorda Therapeutics; Alcobra Ltd.; Alder Biopharmaceuticals Inc.; Allergan, Inc.; Amgen Inc.; Arteaus Therapeutics; Autonomic Technologies, Inc.; Biohaven Pharmaceuticals; BioVentrix; Boston Scientific; Bristol-Myers Squibb Company; Charleston Laboratories, Inc.; CoLucid Pharmaceuticals, Inc.; Dr. Reddy's Laboratories; ElectroCore Medical, LLC; Eli Lilly and Company; eNeura Therapeutics; Ethicon US, LLC; GBS/Nocira; IMPAX Laboratories, Inc.; INSYS Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Labrys Biologics, Inc.; Lundbeck, Inc.; Magellan Health, Inc; MAP Pharmaceuticals, Inc.; Medtronic, Inc; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; NuPathe, Inc.; Pfizer Inc.; Promius Pharma, LLC; St. Jude Medical; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Theranica Bio-Electronics Ltd.; Tonix Pharmaceuticals Holding Corp.; W. L. Gore & Associates, Inc.; Xenon Pharmaceuticals Inc.; Zogenix, Inc.; Zosano Pharma Corporation
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Amgen Inc.; CoLucid Pharmaceuticals, Inc.; Eli Lilly and Company; Medicom; Novartis Pharmaceuticals Corporation
Owns stock, stock options, or bonds from: EPIEN Medical, Inc; Healint; Nocira LLC; Theranica Bio-Electronics Ltd.

Dr Dodick does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Dodick does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

Richard Lipton, MD

Edwin S. Lowe Chair in Neurology
Albert Einstein College of Medicine
Director
Montefiore Headache Center
Bronx, New York

Disclosures

Disclosure: Richard Lipton, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alder Biopharmaceuticals, Inc.; Allergan, Inc.; Amgen Inc.; Autonomic Technologies, Inc.; Avanir Pharmaceuticals; Biohaven Pharmaceuticals; BioVision Inc.; Boston Scientific; Dr. Reddy's Laboratories; ElectroCore Medical, LLC; Eli Lilly and Company; eNeura Therapeutics; GlaxoSmithKline; Merck & Co., Inc.; Pernix Therapeutics; Pfizer Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Trigemina, Inc.; Vector Therapeutics Corp.; Vedanta Biosciences, Inc.
Owns stock, stock options, or bonds from: Biohaven Pharmaceuticals; eNeura Therapeutics

Dr Lipton does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lipton does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Pakinam Aboulsaoud, PharmD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Catherine Friederich Murray BS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Catherine Friederich Murray, BS, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

New Advances in the Targeted Treatment for Migraine

From Medscape Education Neurology & Neurosurgery

CME / ABIM MOC

Getting to Grips With the Science of CGRP and Migraine

Authors: David W. Dodick, MD; Richard Lipton, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 8/24/2018

Valid for credit through: 8/24/2019

processing....

Abbreviations

AE = adverse event
CAD = coronary artery disease
CGRP = calcitonin gene-related peptide
CM = chronic migraine
CVD = cardiovascular disease
EM = episodic migraine
IV = intravenous
mAb = monoclonal antibody
MBS = most bothersome symptom
MHD = migraine headache day
MMD = mean migraine days
PVD = peripheral vascular disease
RDBPC = randomized, double-blind, placebo-controlled
SC = subcutaneous
SF-36 = 36-Item Short-Form Health Survey

« Return to: Getting to Grips With the Science of CGRP and Migraine

CME / ABIM MOC Information Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Moderator

David W. Dodick, MD

Panelist

Richard Lipton, MD

Editors

Pakinam Aboulsaoud, PharmD

Catherine Friederich Murray BS

CME Reviewer(s)

Nafeez Zawahir, MD

CME / ABIM MOC

Getting to Grips With the Science of CGRP and Migraine

Target Audience and Goal Statement

Disclosures

Moderator

David W. Dodick, MD

Panelist

Richard Lipton, MD

Editors

Pakinam Aboulsaoud, PharmD

Catherine Friederich Murray BS

CME Reviewer(s)

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Getting to Grips With the Science of CGRP and Migraine

Abbreviations